Yeah, fair enough. I think I should have worded that a little different. I think it's good to see the company with a drug already approved and on the market with this MoA, Genzyme, sees the utility in further expanding the testing of this kind of drug in oncology. It gives me more confidence in BLRX's chances than had there been no drug with this MoA on the market at all.
Is a small molecule more preferable than a peptide in this type of setting?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.